JP2022527322A5 - - Google Patents

Info

Publication number
JP2022527322A5
JP2022527322A5 JP2021558523A JP2021558523A JP2022527322A5 JP 2022527322 A5 JP2022527322 A5 JP 2022527322A5 JP 2021558523 A JP2021558523 A JP 2021558523A JP 2021558523 A JP2021558523 A JP 2021558523A JP 2022527322 A5 JP2022527322 A5 JP 2022527322A5
Authority
JP
Japan
Prior art keywords
chimeric protein
protein according
optionally
mutations
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527322A (ja
JP7749186B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025419 external-priority patent/WO2020198659A1/en
Publication of JP2022527322A publication Critical patent/JP2022527322A/ja
Publication of JP2022527322A5 publication Critical patent/JP2022527322A5/ja
Priority to JP2025067565A priority Critical patent/JP7891720B2/ja
Application granted granted Critical
Publication of JP7749186B2 publication Critical patent/JP7749186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558523A 2019-03-28 2020-03-27 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質 Active JP7749186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067565A JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825579P 2019-03-28 2019-03-28
US62/825,579 2019-03-28
PCT/US2020/025419 WO2020198659A1 (en) 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067565A Division JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2022527322A JP2022527322A (ja) 2022-06-01
JP2022527322A5 true JP2022527322A5 (cg-RX-API-DMAC7.html) 2023-04-03
JP7749186B2 JP7749186B2 (ja) 2025-10-06

Family

ID=72608957

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558523A Active JP7749186B2 (ja) 2019-03-28 2020-03-27 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質
JP2025067565A Active JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067565A Active JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Country Status (6)

Country Link
US (1) US20220185857A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946409A4 (cg-RX-API-DMAC7.html)
JP (2) JP7749186B2 (cg-RX-API-DMAC7.html)
CN (1) CN113645988A (cg-RX-API-DMAC7.html)
CA (1) CA3133830A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020198659A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
CN114606227B (zh) * 2022-02-22 2024-03-08 复旦大学 高精度腺嘌呤碱基编辑器及其应用
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
RO120919B1 (ro) * 1996-10-25 2006-09-29 G.D. Searle & Co. Proteină hematopoietină, moleculă de acid nucleiccare o codifică, compoziţie farmaceutică şi utilizarea proteinei
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
CA2528595A1 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
WO2013107791A1 (en) * 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
JP6898325B2 (ja) * 2015-12-08 2021-07-07 ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ GM−CSF遺伝子;Flt3L−TRAIL融合遺伝子;TGF−βの発現を抑制するshRNA;およびHSP発現を抑制するshRNAを含む抗腫瘍組成物
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies

Similar Documents

Publication Publication Date Title
Akhlynina et al. Nuclear targeting of chlorin e6 enhances its photosensitizing activity
RU2481398C2 (ru) Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
US10967038B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
US20030194739A1 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP2627346B1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway for use in the treatment of uveitis
WO2004026897A1 (ja) Wt1置換型ペプチド
JP2021522861A (ja) インターロイキン 2突然変異タンパク質およびi型インターフェロンで構成される融合タンパク質
JP2023538071A5 (cg-RX-API-DMAC7.html)
JP2025111546A5 (cg-RX-API-DMAC7.html)
JP2023522588A5 (cg-RX-API-DMAC7.html)
US8303957B2 (en) Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof
JP2024513559A5 (cg-RX-API-DMAC7.html)
Pechar et al. Coiled coil peptides as universal linkers for the attachment of recombinant proteins to polymer therapeutics
JP2018507689A5 (cg-RX-API-DMAC7.html)
JP2022542448A5 (cg-RX-API-DMAC7.html)
CN104619333A (zh) 经修饰的肽,cb受体的配体,用于评估与cb受体结合的试剂盒、体外方法,用于调节cb受体活性的药物组合物、用途
Behi et al. Optimization of PEGylation reaction time and molar ratio of rhG-CSF toward increasing bioactive potency of monoPEGylated protein
CA3247696A1 (en) NEW ANTICANCER IMMUNOTHERAPEUTIC AGENT BASED ON PEPTIDE
CN1157570A (zh) 化学药物向特定细胞的细胞内载运
WO2023138573A1 (zh) 白细胞介素21及其受体复合物
CN116375880A (zh) 融合蛋白及其制备方法和应用
JP5189593B2 (ja) 無差別HER−2/NeuCD4T細胞エピトープ
CN116836261A (zh) 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
US20050277575A1 (en) Therapeutic compositions and methods for treating diseases that involve angiogenesis